Study of Imaging-Guided Hormone and Radiation Therapy for Intermediate- and High-Risk Prostate Cancer in Men

What this Trial Is About

Researchers are evaluating a new imaging approach for men with intermediate- or high-risk prostate cancer who plan to receive hormone therapy and radiation treatment. The study aims to see if using a special imaging test during hormone therapy can help doctors better identify where active cancer remains in the prostate. This could allow for more precise radiation targeting, potentially reducing side effects by avoiding unnecessary treatment to healthy areas. All participants will receive standard hormone therapy androgen deprivation therapy or ADT for about six months, combined with stereotactic body radiation therapy SBRT beginning around 10 weeks after starting ADT. Three PSMA PETCT scans and MRI scans will be performed before hormone therapy begins, about eight weeks after ADT starts before radiation planning, and at 24 weeks end of treatment. Based on these scans, some patients may receive an extra focused radiation boost to areas where active cancer remains, while others may not need this boost if the cancer has responded well. Participants will be monitored with imaging, blood tests measuring PSA levels, and patient-reported quality of life questionnaires focusing on urinary, bowel, and sexual symptoms. Researchers will assess how well the imaging guides radiation planning and treatment targeting. The total participation lasts about six months, during which standard treatments are combined with experimental imaging to improve radiation precision and reduce side effects for future patients.

Androgen-responsive POSLUMA-guided Intra-prostatic Boost